(2R,4S,5R)-2,5-diamino-4-hydroxy-2-(2-methylpropyl)-3-oxo-6-phenylhexanoic acid;hydron;chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,4S,5R)-2,5-diamino-4-hydroxy-2-(2-methylpropyl)-3-oxo-6-phenylhexanoic acid;hydron;chloride
• 化学式: C16H25ClN2O4
• 分子量: 344.8
• InChiKey: JQOATSUOLWQWKR-KHUBKBNHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• [EN] BIOMARKERS OF AMINOPEPTIDASE INHIBITION<br/>[FR] BIOMARQUEURS D'INHIBITION D'AMINOPEPTIDASE
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2009098451A2

  公开（公告）日：2009-08-13

  This invention relates to biomarkers for aminopeptidase inhibition. These biomarkers may be useful, for example, in assessing the extent of aminopeptidase inhibition in vivo or in monitoring cancer treatments using aminopeptidase inhibitors, such as bestatin or CHR-2797.
• [EN] THERAPEUTIC COMBINATION FOR CANCER TREATMENT<br/>[FR] POLYTHÉRAPIE POUR TRAITEMENT DU CANCER
  申请人：STICHTING VUMC

  公开号：WO2019039937A1

  公开（公告）日：2019-02-28

  The invention relates to a composition comprising a statin and an aminopeptidase inhibitor. Said composition may be used as a medicament, including in a method of treating cancer, such as a hematological cancer. The invention further relates to methods of treating a cancer in an individual, and to a use of an aminopeptidase inhibitor in a method for the preparation of a medicament for the treatment of a cancer.